Safety of Intracoronary Administration of c-myc Antisense Oligomers After Percutaneous Transluminal Coronary Angioplasty (PTCA)
- 1 April 2001
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Antisense and Nucleic Acid Drug Development
- Vol. 11 (2) , 99-106
- https://doi.org/10.1089/108729001750171335
Abstract
We wished to assess the clinical safety and pharmacokinetics of ascending doses of a synthetic oligodeoxynucleotide (LR-3280) administered after coronary angioplasty. Antisense oligodeoxynucleotides designed to hybridize with target messenger ribonucleic acid (mRNA) in a complementary fashion to inhibit the expression of corresponding protein also have the ability to bind to extracellular growth factors. LR-3280 has been shown to reduce c-myc expression, inhibit growth and collagen biosynthesis in human vascular cells, and reduce neointimal formation in animal models of vascular injury. After successful percutaneous transluminal coronary angioplasty (PTCA), 78 patients were randomized to receive either standard care (n = 26) or standard care and escalating doses of LR-3280 (n = 52) (doses from 1 to 24 mg), administered into target vessel through a guiding catheter. Overall safety was evaluated by clinical adverse events, laboratory tests, and electrocardiograms. Patency was evaluated by quantitative coronary angiography. There were no clinically significant differences between treated and control patients. No adverse effects of LR-3280 on the patency of dilated coronary arteries were observed. Pharmacokinetic data revealed that peak plasma concentrations of LR-3280 occurred at 1 minute over the studied dose range and rapidly decreased after ~ 1 hour, with little LR-3280 detected in the urine between 0-6 hours and 12-24 hours. The intracoronary administration of LR-3280 is well tolerated at doses up to 24 mg and produces no adverse effects in dilated coronary arteries. These results provide the basis for the evaluation of local delivery of this phosphorothioate oligodeoxynucleotide for the prevention of human vasculoproliferative disease.Keywords
This publication has 19 references indexed in Scilit:
- Vascular MyofibroblastsArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Abrupt (<1 day), acute (<1 week), and early (<1 month) vessel closure at the angioplasty site. Morphologic observations and causes of closure in 130 necropsy patients undergoing coronary angioplastyClinical Cardiology, 1996
- Adventitial Remodeling After Coronary Arterial InjuryCirculation, 1996
- Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular MatrixPublished by Elsevier ,1995
- Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury.Circulation, 1994
- The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig.Circulation, 1994
- Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis.Circulation Research, 1994
- Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.Journal of Clinical Investigation, 1994
- Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells.Circulation, 1993
- A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1993